acetylleucyl-leucyl-norleucinal has been researched along with baicalein in 3 studies
Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (baicalein) | Trials (baicalein) | Recent Studies (post-2010) (baicalein) |
---|---|---|---|---|---|
321 | 0 | 53 | 1,322 | 9 | 839 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (100.00) | 2.80 |
Authors | Studies |
---|---|
Amin, SA; Banerjee, S; Gayen, S; Ghosh, K; Jha, T | 1 |
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
1 review(s) available for acetylleucyl-leucyl-norleucinal and baicalein
Article | Year |
---|---|
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Topics: Antiviral Agents; Catalytic Domain; Coronavirus 3C Proteases; Cysteine Proteinase Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Molecular Docking Simulation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; SARS-CoV-2 | 2021 |
2 other study(ies) available for acetylleucyl-leucyl-norleucinal and baicalein
Article | Year |
---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |